Overall, 192 non-metastatic, non-palliative <i>HER2+</i> breast cancer patients (Luminal B <i>HER2</i>, and <i>HER2+</i> [non-luminal]) were selected (151 adjuvant Trastuzumab treated, 28 neoadjuvant Trastuzumab treated, 13 NACT/ACT Trastuzumab treated). Here, ERBB2 is linked to breast carcinoma.